NLNK fails and TKMR fails left with No choice but BCRX... atleast established a year ago that it works...
“because we’re going to need more than one drug to make sure, because the virus is adapting to us as we’re adapting to it. It mutates into different forms.”
Besides, we all have different DNA, and therefore different ways of reacting to certain drugs. Some drugs that work on one person may not work on another, and vice versa.
“…we’re going to need every single Ebola drug that we have to try to help these patients.”
“That means we’re going to need every single Ebola drug that we have to try to help these patients,” Paul goes on. “And then pray that they work.”
CEO is Garbage+Comedian = Every Lies he speaks he adds YOU KNOW !!!!!!!! Nobody knows only he knows and FDA knows he is bluffing....LOL
Can Stendra save the day?
VIVUS's erectile dysfunction drug, Stendra, was approved by the FDA nearly two years ago. And despite licensing the drug to stronger marketing partners like Auxilium Pharmaceuticals, (NASDAQ: AUXL ) , the drug hasn't made much of an impact on VIVUS's bottom line so far. In the first half of this year, for instance, VIVUS booked only $23.5 million in milestone and licensing revenue from Stendra.
On the bright side, VIVUS and Auxilium recently announced that the FDA approved Stendra's label expansion application, allowing the drug to be taken only 15 minutes before sex. This could help Stendra gain market share against entrenched blockbusters like Viagra and Cialis. That being said, the jury is still out on whether Stendra can turn the tide for VIVUS
Stendra alone can lift VVUS to $10
Breaking ...BUZZ-Orexigen Therapeutics Inc: Diet drug is now officially launched by Takeda with 900 Sales forces..........EMA approval on 24th October
Orexigen Therapeutics Inc. (NASDAQ: OREX) is down a stunning 33% in the past month. The company received approval for its obesity drug Contrave on September 11, and they will be partnering with Takeda Pharmaceutical to launch sales in the coming weeks. While other company’s obesity drugs have had disappointing sales figures, the Merrill Lynch analysts feel that Takeda’s big 900 sales rep force could be a difference maker.
Merrill Lynch has a $9 price target on Orexigen, and the consensus target is even higher at $11. The stock closed on Friday at $4.08.
Past studies have suggested Viagra and other PDE5 inhibitors may have benefits for heart failure by decreasing pulmonary artery resistance and providing cardio-protective effects in settings with low blood flow, according to Kociol.
“They also improve exercise tolerance in patients with heart failure,” he said. The drug may even reduce the size of a heart attack.
Auxilium Pharma recorded Stendra U.S. net revenues of $11.6 million .
Stendra is a highly efficacious ... For the second quarter 2014, "total net revenue was $21.9
Third QTR .............$45?...DOUBLING PATTERN
Now, Auxilium is leaning on one of Stendra's selling points: Its speed. According to its official FDA label, men should take the drug half an hour before they want to get busy. That could give it an edge on well-known older treatments: Eli Lilly's ($LLY) Cialis is taken daily, while Pfizer ($PFE) advises men to take Viagra one to two hours before sex.
Financial Status (as at June 30, 2014)
Cash & Cash Equivalents US$174M
Cash & Available Credits US$885M
Quarterly Dividend US$0.0375/Share
Capitalization (as at June 30,2014)
Common Shares Outstanding (basic): 877.5M
Common Shares Outstanding (fully diluted): 879.6M
Options Outstanding: 2.1M
Yamana Gold has a diversified portfolio of assets providing sustainable gold production supported by a large mineral reserve and mineral resource base. We have industry low cash costs and operations in some of the world’s most stable mining jurisdictions. Yamana offers significant exposure to gold through continued production and mineral resource growth. In 2013 production was 1.2 million GEO and for 2014 we expect production of over 1.42 million GEO.
Estimated Production (millions) 2014E
Total gold equivalent production (GEO) (1) (2) 1.42
Copper production (lbs) (Chapada) 134
Expected Average Cost Structure
AISC by-product cash costs $825-$875/GEO
AISC co-product cash costs $900-$950/GEO
(1) Including production from Alumbrera.
(2) Silver production is treated as a gold equivalent at a ratio of 50:1.
VVUS shares are near a 52 week low.
Stendra has the fastest onset of action in the PDE 5 inhibitor class.
VVUS ' partner, AUXL, just received a takeover bid.
The FDA has approved new labeling for Stendra for use in as little as 15 minutes. Moreover, the marketing partner, Auxilium Pharmacueticals Inc. (NASDAQ:AUXL), just recieved a takeover bid from Endo International (NASDAQ:ENDP). Vivus Pharmaceuticals (NASDAQ:VVUS) shares have fallen dramatically since approval of Qsymia, the second of three new obesity drugs approved recently by the FDA. Price is even off from the approval of the company's second drug, Stendra.